Instem

Instem Rule of 40

Delisted

The Rule of 40 of Instem (INS.L) as of Nov 22, 2026 is 36.49 %. In the previous year, Rule of 40 was 73.44 % — a change of -50.31% (lower).

Rule of 40

36.49 %

YoY

-50.31%

Last updated:

Rule of 40 of Instem is 2022 36.49 % . Rule of 40 of Instem was 2021 73.44 % . It decreases by -50.31% lower compared to the previous year.

The Instem Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2015
29.73 GBP
Jan 1, 2016
12.53 GBP
Jan 1, 2017
18.90 GBP
Jan 1, 2018
18.26 GBP
Jan 1, 2019
24.26 GBP
Jan 1, 2020
23.22 GBP
Jan 1, 2021
73.44 GBP
Jan 1, 2022
36.49 GBP
The Instem Rule of 40 history
YEARRule of 40YoY
36.49 %-50.31%
73.44 %+216.27%
23.22 %-4.27%
24.26 %+32.82%
18.26 %-3.38%
18.90 %+50.89%
12.53 %-57.86%
29.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Instem Stock analysis

What does Instem do? Instem PLC is a company specialized in providing software solutions for the health and life sciences. It is headquartered in Abingdon, Oxfordshire and operates internationally. The company was founded in 2000 and has been listed on the London Stock Exchange since 2004. Instem's business model is based on helping life science companies optimize and automate their workflows. They offer a wide range of software products tailored to the specific needs of their customers. This includes systems for documenting animal experiments, clinical data collection, and solutions for regulatory drug submissions. One of Instem's key divisions is the Preclinical Solutions Division, which helps life science companies effectively plan and conduct their preclinical studies. The products in this division support the creation of study protocols, planning experimental procedures, and documenting study results. Additionally, customers of the Preclinical Solutions Division can access assistance with data collection and analysis, as well as comprehensive consulting services. Another important division of Instem is the Clinical Solutions Division, which supports clinical research facilities in conducting clinical trials. Their solutions include clinical data collection, study monitoring, and data submission to regulatory authorities. The Clinical Solutions Division also provides support for quality control and the production of statistical reports. Instem is also active in other areas, such as in vitro diagnostics and chemical approval. In these fields, the company offers a range of software solutions that aid in data collection, analysis, and reporting. A key factor that sets Instem apart from its competitors is its close collaboration with the life science community. The company works closely with customers, regulatory agencies, and interest groups to ensure that its products meet industry requirements and standards. In addition, the company has established close relationships with leading clinical and research institutions worldwide. In summary, Instem PLC is a significant provider of software solutions for the health and life sciences. The company has experienced impressive growth in recent years and strengthened its position in key market segments. Instem is well positioned to continue benefiting from the increasing demand for software solutions in the health and life sciences industry. Instem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Instem stock

Rule of 40 of Instem is 36.49 % in 2022.

On Eulerpool you can find the complete historical development of Rule of 40 Instem since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Instem

All Key Metrics — Instem